|
" Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. "
Rodríguez, Yhojan; Novelli, Lucia; Rojas, Manuel; De Santis, Maria; Acosta-Ampudia, Yeny; Monsalve, Diana M; Ramírez-Santana, Carolina; Costanzo, Antonio; Ridgway, William M; Ansari, Aftab A; Gershwin, M Eric; Selmi, Carlo; Anaya, Juan-Manuel
| Document Type
|
:
|
AL
|
| Record Number
|
:
|
913112
|
| Doc. No
|
:
|
LA6vw026fd
|
| Title & Author
|
:
|
Autoinflammatory and autoimmune conditions at the crossroad of COVID-19. [Article]\ Rodríguez, Yhojan; Novelli, Lucia; Rojas, Manuel; De Santis, Maria; Acosta-Ampudia, Yeny; Monsalve, Diana M; Ramírez-Santana, Carolina; Costanzo, Antonio; Ridgway, William M; Ansari, Aftab A; Gershwin, M Eric; Selmi, Carlo; Anaya, Juan-Manuel
|
| Date
|
:
|
2020
|
| Title of Periodical
|
:
|
UC Davis
|
| Abstract
|
:
|
Coronavirus disease 2019 (COVID-19) has been categorized as evolving in overlapping phases. First, there is a viral phase that may well be asymptomatic or mild in the majority, perhaps 80% of patients. The pathophysiological mechanisms resulting in minimal disease in this initial phase are not well known. In the remaining 20% of cases, the disease may become severe and/or critical. In most patients of this latter group, there is a phase characterized by the hyperresponsiveness of the immune system. A third phase corresponds to a state of hypercoagulability. Finally, in the fourth stage organ injury and failure occur. Appearance of autoinflammatory/autoimmune phenomena in patients with COVID-19 calls attention for the development of new strategies for the management of life-threatening conditions in critically ill patients. Antiphospholipid syndrome, autoimmune cytopenia, Guillain-Barré syndrome and Kawasaki disease have each been reported in patients with COVID-19. Here we present a scoping review of the relevant immunological findings in COVID-19 as well as the current reports about autoinflammatory/autoimmune conditions associated with the disease. These observations have crucial therapeutic implications since immunomodulatory drugs are at present the most likely best candidates for COVID-19 therapy. Clinicians should be aware of these conditions in patients with COVID-19, and these observations should be considered in the current development of vaccines.
|
| |